Groundbreaking Data Revealed for Genetic Epilepsy Drug STK-001 by Stoke Therapeutics, Exhilarating Investors

1. Stoke Therapeutics Inc. has released updated results from studies involving their antisense oligonucleotide STK-001, demonstrating reduced convulsion seizure frequency in patients with Dravet syndrome.
2. The company announced a $125 million public offering following the positive data for their genetic epilepsy drug, STK-001.
3. New data from Stoke Therapeutics supports the potential of STK-001 as a disease-modifying treatment rather than just managing symptoms.
4. Phase 1/2a studies showed substantial reductions in convulsive seizure frequency among patients treated with 70mg doses of STK-001, with median reductions of 85% at 3 months and 74% at 6 months after the last dose.
5. Open label extension studies indicated durable reductions in seizures and clinically meaningful improvements in multiple measures of cognition and behavior.
6. STK-001 was generally well-tolerated during these trials.
7. Stoke Therapeutics plans to meet with regulatory agencies to discuss registrational study design based on the promising results.